US Denials Of HCV Treatment Coverage Rising, Regardless Of Payer Type
Executive Summary
Trio Health data covering 15,000 patients over three years reveals that 29% of patients failed to start prescribed HCV treatment in 2016, up from 8% in 2104. The "non-starts" appear partially due to denials of coverage by payers and not even the sickest patients have been shielded.